1
|
Feng C, Cui L, Jin Z, Sun L, Wang X, Chi X, Sun Q, Lian S. Construction and comprehensive analysis of the competing endogenous RNA network in endometrial adenocarcinoma. BMC Genom Data 2022; 23:10. [PMID: 35123404 PMCID: PMC8818217 DOI: 10.1186/s12863-022-01028-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2021] [Accepted: 01/19/2022] [Indexed: 12/24/2022] Open
Abstract
Background Endometrial carcinoma (EC) is one of the most common gynecological malignant tumors. In this study, we constructed gene co-expression networks to identify key modules and hub genes involved in the pathogenesis of EC. Results The MEturquoise module was found to be significantly related to hypertension and the MEbrown module was significantly related to the history of other malignancies. Functional enrichment analysis showed that the MEturquoise module was associated with the GO biological process terms of transcription from RNA polymerase II promoter, positive regulation of male gonad development, endocardial cushion development, and endothelial cell differentiation. The MEbrown module was associated with GO terms DNA binding, epithelial-to-mesenchymal transition, and transcription from RNA polymerase II promoter. A total of 10 hub genes were identified and compared with the available datasets at transcriptional and translational levels. Conclusions The identified ceRNAs may play a critical role in the progression and metastasis of EC and are thus candidate therapeutic targets and potential prognostic biomarkers. The two modules constructed further provide a useful reference that will advance understanding of the mechanisms of tumorigenesis in EC. Supplementary Information The online version contains supplementary material available at 10.1186/s12863-022-01028-y.
Collapse
Affiliation(s)
- Chong Feng
- Shengjing hospital affiliated to China medical university, No.36 ,Sanhao street, Heping district, Shenyang, Liaoning province, China
| | - Lei Cui
- School of health management, China medical university, No. 77, Puhe road, Shenbei new district, Shenyang, Liaoning province, China.
| | - Zhen Jin
- Shengjing hospital affiliated to China medical university, No.36 ,Sanhao street, Heping district, Shenyang, Liaoning province, China
| | - Lei Sun
- Shengjing hospital affiliated to China medical university, No.36 ,Sanhao street, Heping district, Shenyang, Liaoning province, China
| | - Xiaoyan Wang
- Shengjing hospital affiliated to China medical university, No.36 ,Sanhao street, Heping district, Shenyang, Liaoning province, China
| | - Xinshu Chi
- Shengjing hospital affiliated to China medical university, No.36 ,Sanhao street, Heping district, Shenyang, Liaoning province, China
| | - Qian Sun
- Shengjing hospital affiliated to China medical university, No.36 ,Sanhao street, Heping district, Shenyang, Liaoning province, China
| | - Siyu Lian
- Shengjing hospital affiliated to China medical university, No.36 ,Sanhao street, Heping district, Shenyang, Liaoning province, China
| |
Collapse
|
2
|
Anand L, Padmavathi V, Dhivya V, Mahalaxmi I, Balachandar V. De novo germ-line mutation of APC gene in periampullary carcinoma with familial adenomatous polyps – A novel familial case report in South India. KARBALA INTERNATIONAL JOURNAL OF MODERN SCIENCE 2016. [DOI: 10.1016/j.kijoms.2016.09.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
3
|
Schildkraut JM, Alberg AJ, Bandera EV, Barnholtz-Sloan J, Bondy M, Cote ML, Funkhouser E, Peters E, Schwartz AG, Terry P, Wallace K, Akushevich L, Wang F, Crankshaw S, Moorman PG. A multi-center population-based case-control study of ovarian cancer in African-American women: the African American Cancer Epidemiology Study (AACES). BMC Cancer 2014; 14:688. [PMID: 25242549 PMCID: PMC4182887 DOI: 10.1186/1471-2407-14-688] [Citation(s) in RCA: 56] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2014] [Accepted: 09/17/2014] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Ovarian cancer (OVCA) is the leading cause of death from gynecological cancer, with poorer survival for African American (AA) women compared to whites. However, little is known about risk factors for OVCA in AA. To study the epidemiology of OVCA in this population, we started a collaborative effort in 10 sites in the US. Here we describe the study and highlight the challenges of conducting a study of a lethal disease in a minority population. METHODS The African American Cancer Epidemiology Study (AACES) is an ongoing, population-based case-control study of OVCA in AA in 10 geographic locations, aiming to recruit 850 women with invasive epithelial OVCA and 850 controls age- and geographically-matched to cases. Rapid case ascertainment and random-digit-dialing systems are in place to ascertain cases and controls, respectively. A telephone survey focuses on risk factors as well as factors of particular relevance for AAs. Food-frequency questionnaires, follow-up surveys, biospecimens and medical records are also obtained. RESULTS Current accrual of 403 AA OVCA cases and 639 controls exceeds that of any existing study to date. We observed a high proportion (15%) of deceased non-responders among the cases that in part is explained by advanced stage at diagnosis. A logistic regression model did not support that socio-economic status was a factor in advanced stage at diagnosis. Most risk factor associations were in the expected direction and magnitude. High BMI was associated with ovarian cancer risk, with multivariable adjusted ORs and 95% CIs of 1.50 (0.99-2.27) for obese and 1.27 (0.85- 1.91) for morbidly obese women compared to normal/underweight women. CONCLUSIONS AACES targets a rare tumor in AAs and addresses issues most relevant to this population. The importance of the study is accentuated by the high proportion of OVCA cases ascertained as deceased. Our analyses indicated that obesity, highly prevalent in this population (>60% of the cases), was associated with increased OVCA risk. While these findings need to be replicated, they suggest the potential for an effective intervention on the risk in AAs. Upon completion of enrollment, AACES will be the largest epidemiologic study of OVCA in AA women.
Collapse
Affiliation(s)
- Joellen M Schildkraut
- Duke Cancer Institute, Department of Community and Family Medicine, Duke University Medical Center, Durham, NC, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
4
|
Lee JS, John EM, McGuire V, Felberg A, Ostrow KL, DiCioccio RA, Li FP, Miron A, West DW, Whittemore AS. Breast and ovarian cancer in relatives of cancer patients, with and without BRCA mutations. Cancer Epidemiol Biomarkers Prev 2006; 15:359-63. [PMID: 16492929 DOI: 10.1158/1055-9965.epi-05-0687] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
BACKGROUND First-degree relatives of patients with breast or ovarian cancer have increased risks for these cancers. Little is known about how their risks vary with the patient's cancer site, carrier status for predisposing genetic mutations, or age at cancer diagnosis. METHODS We evaluated breast and ovarian cancer incidence in 2,935 female first-degree relatives of non-Hispanic White female patients with incident invasive cancers of the breast (n = 669) or ovary (n = 339) who were recruited from a population-based cancer registry in northern California. Breast cancer patients were tested for BRCA1 and BRCA2 mutations. Ovarian cancer patients were tested for BRCA1 mutations. We estimated standardized incidence ratios (SIR) and 95% confidence intervals (95% CI) for breast and ovarian cancer among the relatives according to the patient's mutation status, cancer site, and age at cancer diagnosis. RESULTS In families of patients who were negative or untested for BRCA1 or BRCA2 mutations, risks were elevated only for the patient's cancer site. The breast cancer SIR was 1.5 (95% CI, 1.2-1.8) for relatives of breast cancer patients, compared with 1.1 (95% CI, 0.8-1.6) for relatives of ovarian cancer patients (P = 0.12 for difference by patient's cancer site). The ovarian cancer SIR was 0.9 (95% CI, 0.5-1.4) for relatives of breast cancer patients, compared with 1.9 (95% CI, 1.0-4.0) for relatives of ovarian cancer patients (P = 0.04 for difference by site). In families of BRCA1-positive patients, relatives' risks also correlated with the patient's cancer site. The breast cancer SIR was 10.6 (95% CI, 5.2-21.6) for relatives of breast cancer patients, compared with 3.3 (95% CI, 1.4-7.3) for relatives of ovarian cancer patients (two-sided P = 0.02 for difference by site). The ovarian cancer SIR was 7.9 (95% CI, 1.2-53.0) for relatives of breast cancer patients, compared with 11.3 (3.6-35.9) for relatives of ovarian cancer patients (two-sided P = 0.37 for difference by site). Relatives' risks were independent of patients' ages at diagnosis, with one exception: In families ascertained through a breast cancer patient without BRCA mutations, breast cancer risks were higher if the patient had been diagnosed before age 40 years. CONCLUSION In families of patients with and without BRCA1 mutations, breast and ovarian cancer risks correlate with the patient's cancer site. Moreover, in families of breast cancer patients without BRCA mutations, breast cancer risk depends on the patient's age at diagnosis. These patterns support the presence of genes that modify risk specific to cancer site, in both carriers and noncarriers of BRCA1 and BRCA2 mutations.
Collapse
Affiliation(s)
- Jennifer S Lee
- Division of Epidemiology, Department of Health Research and Policy, Stanford University School of Medicine, HRP Redwood Building, Stanford, California 94305-5405, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Kazerouni N, Greene MH, Lacey JV, Mink PJ, Schairer C. Family history of breast cancer as a risk factor for ovarian cancer in a prospective study. Cancer 2006; 107:1075-83. [PMID: 16881078 DOI: 10.1002/cncr.22082] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
BACKGROUND A family history of breast cancer has been associated with increased ovarian cancer risk. However, few studies have assessed risk according to characteristics that suggest an inherited cancer susceptibility disorder, such as earlier-than-usual age at cancer diagnosis, family members with double primary cancers of different types, multiple relatives with cancer, and cancer in both members of paired organs. METHODS Ovarian cancer risk was assessed according to a detailed breast cancer family history among 49,975 participants in the Breast Cancer Detection Demonstration Project Breast Cancer Defection Demenstration Project (BCDDP) Follow-up Study (1979-1998). In all, 362 incident ovarian cancers were identified during follow-up and rate ratios (RRs) were calculated by Poisson regression. RESULTS.: Breast cancer in a first- or second-degree relative was associated with increased risk of ovarian cancer (RR = 1.4; 95% confidence interval [CI] = 1.1-1.7). Having 2 or more affected first-degree relatives was associated with increased risk (RR = 1.8; 95% CI = 1.1-2.8), especially for women diagnosed with ovarian cancer before age 60 (RR = 4.2; 95% CI = 1.9-9.2) or with a personal history of breast cancer (RR = 3.7; 95% CI 1.8-7.7). Risk was also particularly high for women with 2 or more first-degree relatives with breast cancer and at least 1 affected relative diagnosed before age 50 (RR = 2.6; 95% CI = 1.4-4.8) or with bilateral breast cancer (RR = 4.2; 95% CI = 1.7-10). CONCLUSIONS A detailed breast cancer family history as well as an individual's age and personal history of breast cancer are useful for identifying women at elevated genetic risk of ovarian cancer.
Collapse
Affiliation(s)
- Neely Kazerouni
- Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland 20852-7234, USA
| | | | | | | | | |
Collapse
|
6
|
Chappuis PO, Foulkes WD. Risk assessment & genetic testing. Cancer Treat Res 2002; 107:29-59. [PMID: 11775456 DOI: 10.1007/978-1-4757-3587-1_2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/23/2023]
Abstract
Ovarian cancer is the fifth most common cause of cancer death in women in Western countries and family history is one of the strongest known risk factors. Approximately 5 to 13% of all ovarian cancer cases are caused by the inheritance of cancer predisposing genes with an autosomal pattern of transmission. The inherited fraction of ovarian cancer may differ between populations. Based on analysis of familial ovarian cancer pedigrees and other epidemiological studies, three hereditary ovarian cancer syndromes have been defined. The identification of the genes responsible for most hereditary ovarian cancers has open a new area of early detection methods and preventive procedures specifically dedicated to women identified as carrying ovarian cancer predisposing genes. Predictive oncology is best performed by a dedicated unit with professionals aware of all the issues surrounding genetic testing.
Collapse
Affiliation(s)
- Pierre O Chappuis
- Division of Medical Genetics, Department of Medicine, McGill University Health Center, Montreal, QC, Canada
| | | |
Collapse
|
7
|
Tworek H, Peng R, Fetzer S, Werness BA, Piver MS, Allen HJ, DiCioccio RA. Mutation analysis of BRCA1, TP53, and KRAS2 in ovarian and related pelvic tumors. CANCER GENETICS AND CYTOGENETICS 1999; 112:105-18. [PMID: 10686936 DOI: 10.1016/s0165-4608(98)00267-2] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Cancer may be viewed as a genetic disease resulting from critical mutations that disrupt normal cell growth. To characterize the involvement of the BRCA1 and TP53 tumor suppressor genes and of the KRAS2 protooncogene in gynecologic cancer, mutation analysis of these genes was conducted in pelvic tumors of 85 patients that included 49 epithelial ovarian carcinoma cases. The 85 pelvic tumors contained 5 tumors with BRCA1 mutations, 33 with TP53 mutations, and 1 with a KRAS2 mutation. Each of the BRCA1 and KRAS2 mutations, and 25 of the TP53 mutations, were in ovarian carcinomas. Four of the BRCA1 mutations were germline and 1 was somatic. The 4 patients with germline BRCA1 mutations had an early age of disease onset (33-48 years) relative to the mean age of onset (58 years) of all 49 ovarian carcinoma patients, and 3 of these 4 patients had a family history of ovarian or breast cancer. None of the 4 tumors with germline BRCA1 mutations had a KRAS2 mutation or a TP53 mutation, despite a 51% frequency of TP53 mutations in the 49 ovarian carcinomas. Three of the 4 tumors with germline BRCA1 mutations retained a wild-type BRCA1 allele. The tumor with the somatic BRCA1 mutation contained a TP53 mutation and had no evidence for wild-type BRCA1 and TP53 alleles. These data suggest that both BRCA1 and TP53 were inactivated in 1 of 49 ovarian carcinomas. Moreover, mutational inactivation of both BRCA1 and TP53 did not occur in 4 tumors with a germline BRCA1 mutation. It has been proposed that tumorigenesis in cells with a heterozygous BRCA1 mutation requires inactivation of the wild-type BRCA1 and TP53 alleles, which results in genomic instability and acquisition of mutations in protooncogenes. Clearly, mutational inactivation of TP53 and the wild-type BRCA1 allele in ovarian tumors with a heterozygous, germline BRCA1 mutation is not an absolute requirement for tumor formation. It is possible that these alleles may be inactivated by nonmutational mechanisms or that other tumor formation pathways exist.
Collapse
Affiliation(s)
- H Tworek
- Department of Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
| | | | | | | | | | | | | |
Collapse
|
8
|
Kroser JA, Bachwich DR, Lichtenstein GR. Risk factors for the development of colorectal carcinoma and their modification. Hematol Oncol Clin North Am 1997; 11:547-77. [PMID: 9257146 DOI: 10.1016/s0889-8588(05)70451-2] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
In this article the authors review factors determining risk for the development of colorectal cancer (CC) and their modification. Emphasis is placed on understanding the difference between average risk and high risk individuals. Risk factors including genetics, diet, environment, and coexistent diseases are discussed. The data regarding modification of risk via dietary, pharmaceutical, and prophylactic endoscopic and surgical interventions are reviewed.
Collapse
Affiliation(s)
- J A Kroser
- Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, USA
| | | | | |
Collapse
|
9
|
|
10
|
Easton DF, Matthews FE, Ford D, Swerdlow AJ, Peto J. Cancer mortality in relatives of women with ovarian cancer: the OPCS Study. Office of Population Censuses and Surveys. Int J Cancer 1996; 65:284-94. [PMID: 8575846 DOI: 10.1002/(sici)1097-0215(19960126)65:3<284::aid-ijc2>3.0.co;2-w] [Citation(s) in RCA: 58] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
Mortality from cancer and other causes in first-degree relatives of women with ovarian cancer diagnosed before age 60 has been examined in a large population-based cohort study in England and Wales. Relatives of 1,188 ovarian-cancer cases diagnosed between 1954 and 1981 were identified through a register of households established in 1939. Some 4,111 first-degree relatives living in the same household and having the same surname as the index case were followed up through national records until the end of 1992. Over this period, 1,950 deaths (including 574 cancer deaths) occurred in the relatives. Mortality rates within the cohort were compared with age-, sex- and period-adjusted mortality rates for England and Wales. Mortality from ovarian cancer in first-degree relatives was significantly raised (SMR 223, 95% CI 155-310) although the excess was smaller than that found in case-control studies. The SMR increased with decreasing age of the relative, though not with decreasing age of the index case. After allowing for age, sisters of cases had higher ovarian-cancer mortality than mothers (sister:mother SMR ratio 1.89, p = 0.06). The SMR was greater in individuals having 2 first-degree relatives with ovarian cancer (4 deaths versus 0.17 expected, SMR 242). Relatives of ovarian cancer cases also had significantly increased mortality from cancers of the stomach (SMR 146, 69 deaths) and rectum (SMR 150, 33 deaths), and increased mortality from colon cancer, breast cancer and pancreatic cancer which failed to reach statistical significance. Individuals having a relative with colorectal cancer and a relative with ovarian cancer showed a high mortality from both cancers (11 colorectal-cancer deaths versus 1.23 expected, 4 ovarian-cancer deaths versus 0.66 expected.
Collapse
Affiliation(s)
- D F Easton
- Section of Epidemiology, Institute of Cancer Research, Belmont, Surrey, UK
| | | | | | | | | |
Collapse
|
11
|
Jishi MF, Itnyre JH, Oakley-Girvan IA, Piver MS, Whittemore AS. Risks of cancer among members of families in the Gilda Radner Familial Ovarian Cancer Registry. Cancer 1995; 76:1416-21. [PMID: 8620417 DOI: 10.1002/1097-0142(19951015)76:8<1416::aid-cncr2820760818>3.0.co;2-d] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
BACKGROUND Increasing scientific and public interest in hereditary cancer syndromes has created a need for estimates of lifetime cancer risks among members of families with such syndromes. METHODS Data from the Gilda Radner Familial Ovarian Cancer Registry were used to evaluate risk for cancers of the breast, cervix, uterus, colorectum, and prostate in members of 143 families containing three or more reported cases of ovarian cancer among first- or second-degree relatives. These risks were compared with those that were expected based on general population rates obtained from the Connecticut Tumor Registry. RESULTS Overall, family members' risk of cancer at any nonovarian site was 1.5 times that of the general population (P < 0.001). Among female members, risk for cancer of the breast was 2.5 times that of the general population. Risk for cancer of the uterus was 5 times that of the general population and increased with increasing number of first-degree relatives with ovarian cancer. Among male family members having three or more first-degree relatives with ovarian cancer, prostate cancer risk was 4.5 times that of the general population. No excess risks were observed for cancer of the colorectum. CONCLUSIONS These data support previous reports of coaggregation of cancer of the breast, uterus and ovary, and suggest coaggregation between cancer of the ovary and prostate. Differences in cancer risk profiles observed in these families with multiple ovarian cancer and in carriers of the gene BRCA1 suggest that hereditary ovarian cancer is genetically heterogeneous.
Collapse
Affiliation(s)
- M F Jishi
- Department of Gynecologic Oncology, Roswell Park Cancer Center, New York State Department of Health, Buffalo, USA
| | | | | | | | | |
Collapse
|
12
|
Abstract
A method is described for estimating excess relative risks of a disease from familial factors. Beginning with population-based series of cases and controls, a cohort of each subject's relatives is formed and checked for disease against a population based registry. The disease experience of the cohort formed from each subject's relatives is summarized as a kinship-weighted familial standardized incidence ratio (FSIR). The FSIR's are used as exposure estimates in conditional linear excess relative risk models, which may be used not only to screen for significant familial disease aggregations, but also to estimate relative risks, population attributable risks, and gene-environment interactions. The method is demonstrated on 4083 breast cancer cases from Utah and a set of matched controls.
Collapse
Affiliation(s)
- R A Kerber
- Department of Family and Preventive Medicine, University of Utah, Salt Lake City 84132, USA
| |
Collapse
|
13
|
|
14
|
Abstract
It has been recognized for some time that a family history of breast cancer is associated rather strongly with a woman's own risk of developing the disease. Recent segregation analyses of population-based data on familial patterns provide evidence for a rare autosomal dominant allele that increases a carrier's susceptibility to breast cancer. The estimated proportion of breast cancer patients who carry this allele declines sharply with age at diagnosis. Empirical estimates of the risk associated with particular patterns of family history of breast cancer indicate the following: (1) having any first-degree relative with breast cancer increases a woman's risk of breast cancer 1.5-3-fold, depending on age, (2) having multiple first degree relatives affected is associated with particularly elevated risks, (3) having a second-degree relative affected increases the risk by approximately 50%, (4) affected family members on the maternal side and the paternal side contribute similarly to the risk, (5) a family history of breast cancer is associated with bilateral disease, and (6) breast cancer in males is associated with breast cancer in female relatives in much the same way as is breast cancer in women. Ovarian cancer clearly has been shown to be associated with breast cancer in families, and genetic linkage has provided strong evidence for a breast-ovarian cancer gene located somewhere on chromosome 17q. At the population level, having a first degree relative with ovarian cancer may be at least as predictive of a woman's risk for developing breast cancer as is having a second-degree relative with breast cancer. Considerably weaker evidence points to a possible familial relationship between breast and endometrial cancer and between breast cancer in women and prostatic cancer in males. The clinical applications of the genetic epidemiology of breast cancer are complicated by uncertainty as to the efficacy of mammographic screening in women under the age of 50. For the vast majority of women with a positive family history, the epidemiologic evidence does provide the basis for offering considerable reassurance in that risks are not extremely high. For that rather small subgroup at exceptionally high risk, realistic estimates of the magnitude of absolute risk over the next 10-20 years may be more informative and less alarming than lifetime probabilities.
Collapse
Affiliation(s)
- W D Thompson
- Department of Applied Medical Sciences, School of Applied Science, University of Southern Maine, Portland 04103
| |
Collapse
|
15
|
Claus EB, Risch N, Thompson WD. The calculation of breast cancer risk for women with a first degree family history of ovarian cancer. Breast Cancer Res Treat 1993; 28:115-20. [PMID: 8173064 DOI: 10.1007/bf00666424] [Citation(s) in RCA: 141] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
Recent linkage analyses demonstrate the strength of the genetic association between breast and ovarian cancer in some families. These findings highlight the importance of considering a woman's family history of ovarian cancer in the calculation of her risk of breast cancer. In this study, data on breast and ovarian cancer from the Cancer and Steroid Hormone Study, a large, population-based, case-control study conducted by the Centers for Disease Control, are used to calculate age-specific and cumulative risks of developing breast cancer for a woman with a first degree family history of ovarian cancer. These risks are calculated using maximum likelihood estimates from an autosomal dominant genetic model fit previously to the observed age-specific recurrence data of breast cancer among first degree relatives of the breast cancer cases and controls in these data as well as from genotype-specific estimates of lifetime ovarian cancer risk derived from this model. Under this model, the lifetime risk of developing breast cancer for a woman with one or two first degree relatives affected with ovarian cancer is estimated to be approximately 13% and 31%, respectively. A woman with one first degree relative affected with ovarian cancer and one first degree relative affected with breast cancer has an estimated risk of 40 percent of developing breast cancer by age 79 years if the relative with breast cancer was diagnosed in her thirties. This risk decreases with increasing age of onset of the relative affected with breast cancer.
Collapse
Affiliation(s)
- E B Claus
- Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, Connecticut 06510
| | | | | |
Collapse
|
16
|
Shah S, Evans DG, Blair V, Burnell LD, Birch JM. Assessment of relative risk of second primary tumors after ovarian cancer and of the usefulness of double primary cases as a source of material for genetic studies with a cancer registry. Cancer 1993; 72:819-27. [PMID: 8334636 DOI: 10.1002/1097-0142(19930801)72:3<819::aid-cncr2820720330>3.0.co;2-u] [Citation(s) in RCA: 23] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
BACKGROUND It now is accepted that a small proportion of people with certain forms of cancer have a dominantly inherited gene fault that predisposes them to it. This is more likely with an early age at onset or when the person has had multiple primary tumors. METHODS Population-based data from the North West Regional Cancer Registry of England regarding 4157 ovarian cancer cases diagnosed between 1980 and 1989 were analyzed to determine the relative risks (RR) of second primary breast and colorectal carcinomas. RESULTS Elevated risks approaching significance were observed for breast and colorectal carcinoma subsequent to ovarian cancer. After stratification into groups for ovarian histopathologic characteristics and age at onset, significantly elevated risks were obtained for both breast and colorectal tumors after ovarian carcinoma for women younger than 60 years of age at onset and with serous histopathologic characteristics (breast RR, 2.68, P < 0.05; colorectal RR, 4.25, P < 0.05). CONCLUSIONS These results emphasize the need for greater awareness of the possibility of development of additional cancer after ovarian carcinoma in high-risk groups. Overall, the study supports the theory that breast, colorectal, and ovarian tumors are related genetically.
Collapse
Affiliation(s)
- S Shah
- Cancer Research Campaign (CRC) Paediatric and Familial Cancer Research Group, Christie Hospital, Manchester, United Kingdom
| | | | | | | | | |
Collapse
|
17
|
Yang-Feng TL, Han H, Chen KC, Li SB, Claus EB, Carcangiu ML, Chambers SK, Chambers JT, Schwartz PE. Allelic loss in ovarian cancer. Int J Cancer 1993; 54:546-51. [PMID: 8099899 DOI: 10.1002/ijc.2910540405] [Citation(s) in RCA: 68] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
Loss of heterozygosity (LOH) was examined at 86 loci distributed on every chromosomal arm in 50 human ovarian tumors. Frequent allele losses were observed on chromosomes 13q (42%), 17p (42%), 17q (45%), and Xp (41%). Deletion mapping on chromosome 17 revealed a candidate gene on the long arm distal to D17S41/S74 for ovarian cancer which is distant from the locus for early onset breast cancer. LOH on chromosome 17q was found to be concordant with LOH on chromosomes 3p, 13q, 17p and Xp suggesting that it may be an early event in neoplastic development. These findings indicate that multiple tumor-suppressor genes for ovarian cancer possibly exist on chromosomes 13q, 17, and/or Xp and provide the basis for the identification of candidate gene(s) associated with ovarian cancer. The chromosomal mechanisms resulting in allele losses in ovarian cancer include deletion, deletion/duplication, mitotic recombination and monosomy, in concordance with the developed genetic model.
Collapse
Affiliation(s)
- T L Yang-Feng
- Department of Genetics, Yale University School of Medicine, New Haven, CT
| | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Nelson CL, Sellers TA, Rich SS, Potter JD, McGovern PG, Kushi LH. Familial clustering of colon, breast, uterine, and ovarian cancers as assessed by family history. Genet Epidemiol 1993; 10:235-44. [PMID: 8224804 DOI: 10.1002/gepi.1370100404] [Citation(s) in RCA: 41] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
The aggregation of colon, endometrial, ovarian, and possibly breast cancers in families has been described as a "cancer family syndrome" (now called Lynch syndrome II). To determine if the familial clustering of these malignancies was more common in women with cancer than without, we analyzed data from the Iowa Women's Health Study (IWHS), a population-based sample of 41,837 women aged 55-69 years. Self-reported information was collected on history of colon, uterine, ovarian, and breast cancers in female first-degree relatives. A family history of cancer of the breast (odds ratio [OR] = 1.4), colon (OR = 1.3), and uterus (OR = 1.3), but not ovary (OR = 1.2), was significantly more common among women with a personal history of any of these four cancers (all P < 0.05); the pattern of the ORs suggested strongly that the clustering tended to be site-specific. Age-adjusted relative risks (RR) of incident colon cancer over 5 years of follow-up (N = 237) were calculated with regard to family history. Colon cancer incidence was increased among women with a family history of breast (RR = 1.3), uterine (RR = 1.4), colon (RR = 1.5), and ovarian (RR = 1.3) cancers, although none of the risk estimates achieved statistical significance. RR was, however, significantly related to the number of different cancer sites reported among family members (Ptrend = 0.008). These data on a representative sample of postmenopausal women suggest that family histories of colon, breast, uterine, and ovarian cancers are associated with an increased risk of cancer at the same site, but provide little support for the hypothesis that Lynch syndrome II is a non-random occurrence.
Collapse
Affiliation(s)
- C L Nelson
- Division of Epidemiology, School of Public Health, University of Minnesota, Minneapolis 55454
| | | | | | | | | | | |
Collapse
|
19
|
Abstract
A subject from a family with ovarian cancer who has developed bilateral medullary carcinoma of the breast at the age of 40 is presented. The family is consistent with dominant inheritance of ovarian cancer and 12 female family members at 12.5%, 25%, and 50% risk, including our case, have undergone bilateral prophylactic oophorectomy and been given hormone replacement therapy. Despite the risk of further primary tumours of the breast our patient chose to have treatment with wide excision and radiotherapy. The implications for screening, prophylaxis, and hormone replacement therapy for this family are discussed.
Collapse
Affiliation(s)
- D G Evans
- CRC Department of Cancer Genetics, Paterson Institute for Cancer Research, Christie Hospital, Manchester
| | | | | | | |
Collapse
|
20
|
Rosenblatt KA, Thomas DB, Noonan EA. High-dose and low-dose combined oral contraceptives: protection against epithelial ovarian cancer and the length of the protective effect. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Eur J Cancer 1992; 28A:1872-6. [PMID: 1389530 DOI: 10.1016/0959-8049(92)90026-x] [Citation(s) in RCA: 38] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
The relations between use of high-dose and low-dose combined oral contraceptives and epithelial ovarian cancer were compared in an international hospital-based case-control study. 393 cases from seven countries were compared with 2561 matched controls. The odds ratio (OR) was somewhat lower for women who used high-dose oestrogen oral contraceptives (OR = 0.68) than for women who used low-dose preparations (OR = 0.81) although the difference could have occurred by chance. After controlling for time since last use, risk was slightly lower for long-term users of high-dose preparations than for long-term users of low-dose pills. Both high-dose and low-dose oral contraceptives protect against ovarian cancer, but the degree of protection may be slightly weaker for the newer, low-dose products.
Collapse
Affiliation(s)
- K A Rosenblatt
- Fred Hutchinson Cancer Research Center, Seattle, Washington 98104
| | | | | |
Collapse
|
21
|
Affiliation(s)
- R A DiCioccio
- Department of Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, New York 14263
| | | |
Collapse
|
22
|
Rosenblatt KA, Thomas DB. Hormonal content of combined oral contraceptives in relation to the reduced risk of endometrial carcinoma. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Int J Cancer 1991; 49:870-4. [PMID: 1959990 DOI: 10.1002/ijc.2910490612] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
The relationship between the strength of the estrogenic and progestational components of combined oral contraceptives and risk of endometrial carcinoma was examined in a multinational hospital-based case-control study comparing 220 cases from 7 countries with 1,537 age- and hospital-matched controls. Oral contraceptives were classified according to their relative content of estrogen and progestin. The risk was not altered in women who used preparations containing high-dose estrogen/low-dose progestin compounds [odds ratio (OR) = 1.10, 95% CI = 0.13-9.96]. In contrast, the risk among users of low-dose estrogen/high-dose progestin oral contraceptives was greatly decreased (OR = 0, 95% CI = 0-1.08). Risks observed for users of high-dose estrogen/high-dose progestin (OR = 0.15, 95% CI = 0.045-0.50) and low-dose estrogen/low-dose progesterone (OR = 0.59, 95% CI = 0.26-1.30) preparations were intermediate between those for users of the 2 other types of preparation. A significantly lower risk was observed for high-dose progestin users than for low-dose users [ratio of odds ratios (ROR) = 0.21, 95% CI = 0.05-0.84]. Although the numbers are small, findings from this study suggest that combined oral contraceptives with varying strengths of estrogen and progestin have different effects on the risk of endometrial carcinoma.
Collapse
Affiliation(s)
- K A Rosenblatt
- Fred Hutchinson Cancer Research Center, Seattle, WA 98104
| | | |
Collapse
|
23
|
Ovarian Cancer. Hematol Oncol Clin North Am 1991. [DOI: 10.1016/s0889-8588(18)30385-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
|
24
|
Abstract
Substantial progress has been made in understanding the biologic behavior of ovarian cancer and in assessing disease states and response to therapy with transvaginal sonography, CT scan, and tumor markers such as CA-125. There is no longer controversy regarding the importance and feasibility of adequate surgical staging, the need for cytoreduction, and the utility of cisplatin- or carboplatin-based combination chemotherapy in the management of patients with ovarian cancer. Increasing chemotherapy dose through escalated systemic doses or intraperitoneal administration, revising multidrug resistance, the use of biologic response modifiers, and the development of new methods of chemosensitivity testing may help improve the current 5-year survival rate of less than 30% for patients with stage III ovarian cancer. Significant improvement in screening tests and diagnostic capabilities will be necessary for a dramatic increase in survival.
Collapse
Affiliation(s)
- G Deppe
- Division of Gynecologic Oncology, Wayne State University School of Medicine, Hutzel Hospital, Detroit, Michigan
| | | |
Collapse
|
25
|
Greggi S, Ponder BA, Mancuso S. Establishment of a European registry for familial ovarian cancer. Eur J Cancer 1991; 27:113-5. [PMID: 1827269 DOI: 10.1016/0277-5379(91)90464-o] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
|
26
|
Andrieu N, Clavel F, Auquier A, Gairard B, Brémond A, Lansac J, Piana L, Flamant R, Renaud R. Association between breast cancer and family malignancies. Eur J Cancer 1991; 27:244-8. [PMID: 1827304 DOI: 10.1016/0277-5379(91)90506-9] [Citation(s) in RCA: 22] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
In a case-control study, the relationship between a family history of cancer of the breast, ovary, colon, uterus or prostate and the risk of breast cancer was investigated. The data consisted of family histories from 495 breast cancer cases and 785 controls aged 20-56 years. A positive association was found between the occurrence of breast cancer and a history of breast cancer in the families of the subjects affected. This relationship increased linearly with both the degree of kinship of the affected relatives and with their number. The risk of breast cancer associated with other types of cancer in the family was not significantly different from unity.
Collapse
Affiliation(s)
- N Andrieu
- Unité de Recherche en Epidémiologie des Cancers, Institut Gustave Roussy, Villejuif, France
| | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Sellers TA, Potter JD, Folsom AR. Association of incident lung cancer with family history of female reproductive cancers: the Iowa Women's Health Study. Genet Epidemiol 1991; 8:199-208. [PMID: 1955154 DOI: 10.1002/gepi.1370080306] [Citation(s) in RCA: 43] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
A number of studies have documented the familial aggregation of lung cancer; there is at least one report that female reproductive cancers are also increased in these families. To determine if the risk exists for all reproductive cancer sites, we conducted a nested case-control study of lung cancer incidence in a cohort of 41,837 women ages 55-69 years. Women were recruited by mail and asked to provide information on education, occupation, smoking habits, physical activity, and family history of specific cancer sites among female relatives. Four year follow-up for cancer incidence was conducted using a state-wide tumor registry. Compared to random controls (n = 1900), cases (n = 152) were more likely to have reported at baseline a sister affected with cancer of the uterus [crude odds ratio (OR) = 3.4, 95% Cl = 1.7-7.0, P less than 0.01], cervix (OR = 3.2, 95% Cl 1.2-8.6, P less than 0.05), or cancer at any site (OR = 1.6, 95% Cl 1.1-2.4, P less than 0.05). A family history of an affected mother with a female reproductive cancer was also more common among the cases, but not statistically significant. Cases were less educated, more likely to work in a technical/industrial setting, less physically active, more likely to smoke, and to smoke for a longer period of time than the controls (all P less than 0.01). These differences reduced the magnitude of the family history risk indicators; only the combined category of reproductive cancer at all sites among sisters remained statistically significant. Additional family studies should be done to assess environmental factors in the relatives of the cases and controls to disentangle the influence of shared genes and shared environmental factors in these associations.
Collapse
Affiliation(s)
- T A Sellers
- Division of Epidemiology, School of Public Health, University of Minnesota, Minneapolis
| | | | | |
Collapse
|
28
|
Greggi S, Genuardi M, Benedetti-Panici P, Cento R, Scambia G, Neri G, Mancuso S. Analysis of 138 consecutive ovarian cancer patients: incidence and characteristics of familial cases. Gynecol Oncol 1990; 39:300-4. [PMID: 2258075 DOI: 10.1016/0090-8258(90)90256-k] [Citation(s) in RCA: 30] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Eight families with two or more first-degree relatives affected with ovarian carcinoma were identified among a series of 138 consecutive ovarian cancer patients. History of breast cancer was reported in six of the eight families. Five of 19 patients with familial cancer developed ovarian cancer as a second primary tumor following breast carcinoma, whereas only 6/130 sporadic cases had a previous history of breast cancer. No significant difference was detected in clinical and pathological features between sporadic and familial cases. However, in three high-risk families ovarian cancer tended to develop at a younger age compared with other familial cases and with sporadic occurrences, and nulliparity was less frequent in the familial group. These observations emphasize the need to take into account multiple factors-in addition to positive family history-for the evaluation of genetic predisposition to ovarian carcinoma.
Collapse
Affiliation(s)
- S Greggi
- Istituto di Clinica Ginecologica e Ostetrica, Facoltà di Medicina e Chirurgia A. Gemelli, Università, Cattolica del Sacro Cuore, Rome, Italy
| | | | | | | | | | | | | |
Collapse
|
29
|
Abstract
Information on family history and age of onset of breast cancer is examined in an attempt to distinguish between postulated early and late onset forms of breast cancer and to estimate the familial correlation between any subforms that may exist. Data are taken from the Cancer and Steroid Hormone Study, a multicentre, population-based, case-control study conducted by the Centers for Disease Control (CDC). The data set includes 4730 histologically confirmed breast cancer cases aged 20-54 and 4688 controls who were frequency-matched to cases by geographic region and five-year categories of age. Data regarding family history of breast cancer for mothers and sisters of cases and controls are used in this analysis. The methods of Smith (1976) are modified to obtain maximum likelihood estimates of heritability and familial correlation using 35, 40, 45, and 50 years of age as the dividing point between early and late onset. The heritabilities for both the early and late onset forms decrease and approach one another in size with increasing age cutpoint, although the heritability for the early group is always greater than that for the late group. Irrespective of cutpoint, the familial correlation between the two groups does not differ significantly from one, providing evidence for a single genetic form of breast cancer with familial cases increasingly represented among cases with earlier onset.
Collapse
Affiliation(s)
- E B Claus
- Department of Epidemiology, Yale University School of Medicine, New Haven, CT 06510
| | | | | |
Collapse
|